---
title: "Policy Pulse — Global Trade — 06 Jul 2026"
ticker: "SUNPHARMA:DRREDDY:CIPLA:DIVIS:AUROPHARMA:TCS:INFY:WIPRO:HCLTECH:TATASTEEL:JSWSTEEL:WELSPUN:TRIDENT:PAGEIND:RAYMOND"
date: "2026-07-06"
tags: ["policy-pulse", "global-trade", "ustr", "tariffs", "forced-labour", "india-us-trade", "pharma", "textiles", "stocks"]
summary: "USTR forced labor tariff hearings Jul 7-9 propose 12.5% duty on 60 economies including India; US pharma tariffs (100% on patented) exclude generics — Neutral for Indian API exporters; USMCA not renewed; Brazil tariff deadline Jul 15. Stocks: SUNPHARMA, DRREDDY, DIVIS, TCS, INFY, TATASTEEL, WELSPUN, RAYMOND."
model: "deepseek-chat"
---

# Policy Pulse — Global Trade — 06 Jul 2026

## 🌍 Global Trade Alert: USTR Forced Labor Tariff Hearings, Pharma Tariffs, and Trade Deal Deadlines

**Date:** 06 Jul 2026
**Categories:** Tariffs, Trade Deals, Sanctions/Export Controls
**Tickers impacted (India):** SUNPHARMA, DRREDDY, CIPLA, DIVIS, AUROPHARMA, TCS, INFY, WIPRO, HCLTECH, TATASTEEL, JSWSTEEL, WELSPUN, TRIDENT, RAYMOND, PAGEIND, BHARATFORG, INDUSIND, AARTIIND, SRF, GEPIL, CEAT
**Tickers impacted (US):** N/A — Indian policy, Indian stocks only

---

## 1. USTR Forced Labor Tariff Hearings — Jul 7-9, 2026

**What happened:** The U.S. Trade Representative opens public hearings July 7-9 on proposed Section 301 tariffs against **60 economies** found to have failed in enforcing forced labor import prohibitions. USTR has proposed **12.5% tariff** on over 50 countries including India, with a lower 10% tier for others. The hearings begin tomorrow, with the Section 122 global 10% tariff expiring **July 24, 2026**.

**Key details:**
- USTR hearings: July 7-9 (Tue-Thu)
- Current 10% Section 122 tariff expires: July 24
- Replacement: Proposed 12.5% forced labor tariffs (tier 2) on India, China, Vietnam, Thailand, Japan, South Korea + others
- Second probe (structural overcapacity): Still pending — being used as bargaining chip for bilateral deals
- India-US trade deal negotiations ongoing but stalled pending final U.S. tariff plan
- India seeking "comparative advantage" over China, Vietnam, Bangladesh, ASEAN

**Irony:** The 10% → 12.5% increase may actually **benefit Indian exporters** vs competitors if it's uniformly applied — India's competitors (Bangladesh, Vietnam, China) would face the same increase. Indian exporters "heave a sigh of relief" per TOI.

### Stock Impact — USTR Tariffs

| Stock (India) | Ticker | Impact | Reason |
|---------------|--------|:------:|--------|
| **Textiles — Large cap** | | | |
| Welspun Living | WELSPUN | 🟡 HOLD | Textile exports to US could face 12.5% instead of 10% — manageable increase, but uncertainty over USTR final tier |
| Trident | TRIDENT | 🟡 HOLD | Same as above; home textile exposure to US market |
| Raymond Lifestyle | RAYMOND | 🟢 BUY | Shifting 8% of exports from US to UK/Europe via India-UK CETA; diversification reduces US tariff risk |
| Page Industries | PAGEIND | 🟡 HOLD | Premium innerwear; US exposure limited but sentiment impact |
| Vardhman Textiles | VTL | 🟡 HOLD | Yarn/fabric exports to US; indirect exposure |
| **Pharma — Generic exports** | | | |
| Sun Pharma | SUNPHARMA | 🟢 BUY | Generics EXCLUDED from 100% patented pharma tariffs; Indian generic API exports unaffected |
| Dr Reddy's | DRREDDY | 🟢 BUY | Generics-focused, strong US generic portfolio — no Section 232 impact |
| Divi's Labs | DIVIS | 🟢 BUY | API manufacturer; generics excluded from 100% tariff |
| Cipla | CIPLA | 🟢 BUY | Strong US generics business; no direct tariff hit |
| Aurobindo Pharma | AUROPHARMA | 🟢 BUY | Large US generic portfolio; tariff-immune |
| **IT Services** | | | |
| TCS | TCS | 🟡 HOLD | H-1B visa policy risk remains; tariff uncertainty may delay US client IT spending decisions |
| Infosys | INFY | 🟡 HOLD | Same — US policy uncertainty creates deal-decision drag |
| **Metals** | | | |
| Tata Steel | TATASTEEL | 🟡 HOLD | Steel exports to US already under Section 232; forced labor tariff would stack additional burden |
| JSW Steel | JSWSTEEL | 🟡 HOLD | Same — stacked tariffs = higher landed cost in US |
| **Chemicals** | | | |
| Aarti Industries | AARTIIND | 🟡 HOLD | Chemical intermediates exported to US; tariff layer adds cost |
| SRF | SRF | 🟢 BUY | Specialty chemicals and packaging films; diversified export base reduces single-market risk |

**Confidence score:** 4/5 — USTR has published proposed rates, hearings are scheduled, timeline is known (Jul 24 deadline)

**Source:** [TOI — USTR probe action creates uncertainty for India](https://timesofindia.indiatimes.com/business/india-business/ustr-probe-action-creates-uncertainty-for-india-others/articleshow/132204915.cms)

---

## 2. US Pharma Tariffs — 100% on Patented Drugs, Generics Excluded

**What happened:** Trump's April 2, 2026 Section 232 Proclamation imposes **100% ad valorem tariff** on imported patented pharmaceutical products and APIs. However, **generic pharmaceuticals, biosimilars, and their associated ingredients are expressly excluded**. The tariff took effect July 31, 2026 for 17 named large pharma companies, and September 29, 2026 for all others.

**What this means for India:**
- India's core pharma export business is **overwhelmingly generic** — NOT directly affected
- A White House official specifically confirmed generics "shall not be subject to Section 232 tariffs at this time"
- Indian API exporters (Divi's, Aurobindo, Dr Reddy's) to US-bound formulators remain on competitive footing

### Stock Impact — US Pharma Tariffs

| Stock (India) | Ticker | Impact | Reason |
|---------------|--------|:------:|--------|
| Divi's Labs | DIVIS | 🟢 BUY | API manufacturer; generics excluded, business as usual for 95%+ of exports |
| Aurobindo Pharma | AUROPHARMA | 🟢 BUY | Large US generics + API; no tariff impact |
| Dr Reddy's | DRREDDY | 🟢 BUY | Generics focused; zero tariff impact |
| Laurus Labs | LAURUS | 🟢 BUY | API + generics; tariff-immune |
| Glenmark | GLENMARK | 🟢 BUY | Generics to US; tariff-exempt category |
| Biocon | BIOCON | 🟢 BUY | Biosimilars excluded; Syngene CRO business unaffected |

**Confidence score:** 5/5 — Official proclamation text, White House clarification, and legal analysis confirm generics exclusion

**Source:** [Chemox Pharma — US Pharma Tariffs 2026 India](https://chemoxpharma.com/us-pharma-tariffs-2026-india)

---

## 3. USMCA Not Renewed — Annual Reviews Begin

**What happened:** The Trump administration declined to renew the USMCA trade agreement (Trump's own 2020 replacement for NAFTA). The agreement doesn't expire immediately, but goes into annual reviews with a 10-year clock toward expiration. Effectively, the US is the lone holdout as the agreement continues on autopilot.

**Stock impact:** Minimal direct India impact. However, it signals continued US unilateralism on trade.

| Stock | Impact | Reason |
|-------|:-----:|--------|
| Global supply chains | 🟡 HOLD | Continued uncertainty on North American supply chain arrangements |

**Confidence:** 3/5 — Analysis from trade commentators; no immediate policy change

---

## 4. Brazil Tariff Deadline — July 15

**What happened:** The US has until July 15 to decide whether to impose proposed 25% tariffs on Brazilian goods. Senator Flavio Bolsonaro is lobbying Washington to delay until after Brazil's October election. Exempt products: beef, coffee, rare earths, aircraft parts.

**Stock impact:** Low direct India impact, but sets precedent for US tariff action against trading partners.

---

## 📌 Actionable Ideas — Summary

| Stock | Ticker | Direction | Confidence | Thesis |
|-------|--------|:---------:|:----------:|--------|
| Sun Pharma | SUNPHARMA | 🟢 BUY | 4/5 | Generics tariff-excluded; strong US franchise unfazed |
| Dr Reddy's | DRREDDY | 🟢 BUY | 4/5 | Same thesis; generics immune from 100% pharma tariff |
| Divi's Labs | DIVIS | 🟢 BUY | 4/5 | API maker; generics exclusion protects revenue |
| Raymond Lifestyle | RAYMOND | 🟢 BUY | 3/5 | Diversifying away from US to UK/Europe via CETA; reduces tariff risk |
| SRF | SRF | 🟢 BUY | 3/5 | Diversified exports; less single-market vulnerability |
| Welspun Living | WELSPUN | 🟡 HOLD | 3/5 | US textile exposure; wait for USTR final tier assignment |
| TCS | TCS | 🟡 HOLD | 3/5 | H-1B policy risk; US tariff uncertainty delays IT spending |
| Tata Steel | TATASTEEL | 🟡 HOLD | 3/5 | Already under Section 232; forced labor tariff would stack |

---

## ⚠️ Key Dates to Watch

| Date | Event | Impact |
|------|-------|--------|
| **Jul 7-9** | USTR forced labor tariff hearings (~60 countries) | High — tier assignments + effective date |
| **Jul 15** | Brazil tariff deadline (25% proposed) | Medium — precedent for USTR enforcement |
| **Jul 15** | India-UK CETA effective date | High — zero duty access for Indian exports |
| **Jul 24** | Section 122 global 10% tariff expires | High — must be replaced or market disruption |
| **Aug 1** | SEBI open market buyback reintroduced | Positive for Indian markets |
| **Q3 2026** | USTR final forced labor tariff rule expected | High — actual duty rate + country list |
| **Jul 31** | Section 232 100% pharma tariff for named companies | Already priced for named big pharma |
| **Sep 29** | Section 232 pharma tariff for all other importers | Watch for potential generics inclusion |

---

## 📌 Cumulative Weekly Sector Tilt

| Sector | This Week Signals | Net Direction |
|--------|-------------------|:------------:|
| Indian Pharma (Generics) | USTR generics exclusion confirmed; 100% patented tariff doesn't apply | 🟢 Positive |
| Indian Textiles | US forced labor tariff uncertainty vs UK CETA opportunity | 🟡 Mixed |
| Indian IT Services | US tariff uncertainty delays client decisions; H-1B risk overhang | 🟡 Cautious |
| Indian Steel | Stacked tariffs (Section 232 + forced labor) = headwind | 🔴 Negative |
| Indian Chemicals | Diversified exporters better positioned than single-market players | 🟡 Mixed |

---

*Analysis date: 06 Jul 2026 | Sources: USTR, TOI, ET CFO, Bloomberg, Reuters, Chemox Pharma | Confidence scores are indicative, not investment advice*